Form Type: 4

SEC EDGAR Link
Accession Number:0001358403-16-000273
Date:2016-09-21
Issuer: BELLICUM PHARMACEUTICALS, INC (BLCM)
Original Submission Date:

Reporting Person:

SLAWIN KEVIN M.
C/O BELLICUM PHARMACEUTICALS, INC.
2130 W. HOLCOMBE BLVD., STE. 800 HOUSTON, TX 77030

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2016-09-21 S 100 d $20.04 95,464 direct
COMMON STOCK 2016-09-21 S 100 d $20.04 366,940 indirect f2
COMMON STOCK 2016-09-23 S 11,258 d $20.12 84,206 direct
COMMON STOCK 2016-09-23 S 11,958 d $20.11 354,982 indirect f2
COMMON STOCK 2016-09-21 0 $0.00 398,067 indirect f3
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 the sales reported in this form 4 were effected pursuant to a rule 10b5-1 trading plan adopted on march 23, 2016 by the reporting person.
f2 the reporting person's spouse is trustee of the jordana slawin 2012 family trust. the reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of section 16 or for any other purpose.
f3 the reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of section 16 or for any other purpose.
f4 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $20.00 to $20.55, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range.
f5 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $20.00 to $20.29, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range.
WhaleWisdom Logo

Elevate your investments